Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of diffuse large B-cell\* or peripheral T-cell non-Hodgkin's lymphoma by REAL/WHO classification, including the following:~  * All morphological and clinical variants~ * All Ann Arbor stages NOTE: \*Presence of a small cell, indolent lymphoma component in the bone marrow biopsy is allowed~* No Burkitt-like lymphoma~* Previously untreated disease~* No cerebral or meningeal involvement~* At least 1 measurable target lesion at least 1.1 cm by the Cheson criteria~PATIENT CHARACTERISTICS:~Age~* 70 and over~Performance status~* WHO 0-2~Life expectancy~* Not specified~Hematopoietic~* Absolute neutrophil count greater than 1,500/mm\^3~* Platelet count greater than 100,000/mm\^3 (unless related to bone marrow infiltration)~Hepatic~* Bilirubin less than 1.8 mg/dL\*~* AST or ALT less than 2.5 times upper limit of normal (ULN)\*~* Alkaline phosphatase less than 4 times ULN\* NOTE: \*Values above these thresholds are allowed only if related to non-Hodgkin's lymphoma~Renal~* Creatinine clearance at least 50 mL/min~Cardiovascular~* LVEF at least 50%~Other~* HIV negative~* No history of concurrent severe disease that would preclude study treatment~* No other prior or concurrent malignancy except adequately treated basal cell skin cancer, curatively treated carcinoma in situ of the cervix, or other curatively treated solid malignancy with no evidence of disease for at least 5 years prior to study entry~* No psychological, familial, sociological, or geographical condition that would preclude study compliance and follow-up~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* Not specified~Endocrine therapy~* Not specified~Radiotherapy~* Not specified~Surgery~* Not specified~Other~* No concurrent participation in another investigational drug study~* No other concurrent antineoplastic agents

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).